|
| Trials | Location | Design of trial | Duration (m) | Original patients (eyes) | Dropouts | Mean age ± SD (range) (M/F) | System baselines | Ocular baselines |
|
| Salehi et al. [11] | Iran | Prospective, randomized controlled trial | 6 | (1): 27 (27)
(2): 30 (30) | (1): 0 (0)
(2): 0 (0) | (1): 61.5 ± 12.7 (14/13)
(2): 62.3 ± 14 (17/13) | NS: DM type and duration, hypertension duration | NS: BCVA, MT |
| Fard et al. [12] | Iran | Prospective, randomized controlled trial | 6 | (1): 31 (31)
(2): 32 (32) | (1): 0 (0)
(2): 2 (2) | (1): 64 ± 4 (13/18)
(2): 62 ± 5 (15/15) | NS: DM type and duration, coronary artery disease percentage, HbA1c level, hypertension duration | NS: BCVA, MT |
| Takamura et al. [13] | Japan | Prospective, randomized, masked cohort study. | 3 | (1): 21 (21)
(2): 21 (21) | (1): 0 (0)
(2): 0 (0) | (1): 67.3 ± 5.2 (9/12)
(2): 69.1 ± 5.9 (10/11) | NS: DM duration, HbA1c level | NS: cataract severity (LOCS), BCVA, RT |
| Lanzagorta-Aresti et al. [14] | Spain | Prospective, randomized pilot study | 6 | (1): 13 (13)
(2): 13 (13) | (1): 0 (0)
(2): 0 (0) | NS: age and sex. | NR | NS: BCVA, MT |
| Cheema et al. [15] | Kingdom of Saudi Arabia | Prospective, randomized controlled trial | 6 | (1): 35 (35)
(2): 33 (33) | (1): 0 (0)
(2): 0 (0) | (1): 66.14 (22/13)
(2): 64.5 (21/12) | NS: DM type and duration, hypertension duration | NS: retinopathy and maculopathy type, BCVA, MT |
| Chae et al. [16] | Korea | Prospective randomized study | 6 | (1): 40 (40)
(2): 40 (40) | (1): 1 (1)
(2): 3 (3) | (1): 62.9 (21/18)
(2): 67.2 (20/17) | NS: DM type | NS: BCVA, CST, TMV, PRP history |
| Lin et al. [17] | China | Prospective, randomized controlled trial | 6 | (1): 23 (23)
(2): 23 (23) | (1): 0 (0)
(2): 0 (0) | (1): 64.6 (8/15)
(2): 65.5 (10/13) | NR | NS: BCVA, MT |
| Lu et al. [18] | China | Nonrandomized comparative study | 6 | (1): 17 (19)
(2): 18 (19) | (1): 0 (0)
(2): 0 (0) | (1): 59.59
(2): 57.56 | NR | NS: BCVA, MT, IOP |
| Cheng et al. [19] | China | Nonrandomized comparative study | 6 | (1): 43 (64)
(2): 43 (63) | (1): 0 (0)
(2): 0 (0) | (1): 43.3 (20/23)
(2): 42.7 (19/24) | NR | NS: BCVA, MT |
| Li [20] | China | Prospective, randomized controlled trial | 6 | (1): 20 (24)
(2): 18 (19) | (1): 0 (0)
(2): 0 (0) | (1): 59.6
(2): 59.1 | NS: DM type | NS: BCVA, MT, IOP |
| Chen et al. [21] | Taiwan | Retrospective comparative study | 3 | (1): 14 (15)
(2): 14 (14) | (1): 0 (0)
(2): 0 (0) | (1): 66 (6/8)
(2): 65 (7/7) | NS: age, sex, eye laterality | NS: BCVA, MT |
| Udaondo et al. [22] | Spain | Prospective, randomized controlled trial | 3 | (1): 27 (27)
(2): 27 (27) | (1): 0 (0)
(2): 0 (0) | (1): 68.9 ± 4.7 (10/17)
(2): 72.8 ± 5.2 (9/18) | NS: age, sex | NS: MT |
|
